At the start of year-end reporting season, businesses can find themselves facing many questions about forms and deadlines. With the introduction of the Affordable Care Act in 2014, the waters got even muddier.
Greatland Corporation, an expert in forms and reporting, has developed a helpful outline for businesses facing reporting questions.
• If your business employs 50 or more full-time equivalent employees and is self-insured, you need to file Form 1095-C Parts I, II and III.
• If your business employs 50 or more full-time equivalent employees and you are NOT self-insured, you need to file Form 1095-C Parts I and II only.
• If you are a self-insured employer with less than 50 full-time equivalent employees, you are required to file Form 1095-B, Parts I, III and IV.
To view the multimedia release go to:
https://www.multivu.com/players/English/8218651-greatland-corporation-year-end-tax-reporting-advice/
Since Newton witnessed a bubble rising from his bathtub, mankind has sought the stars. When William III of England commissioned Capt. William Kidd to command the first expedition to Mars in the late 1600s, he proved that space travel was both possible and profitable.
The Adventures of Arabella Ashby series by David D. Levine, beginning with Arabella of Mars and continuing in Arabella and the Battle of Venus, offers adventure, romance, political intrigue, and Napoleon in space!
Find out more at- https://us.macmillan.com/series/theadventuresofarabellaashby Scifi/Fantasy
Dornier MedTech® America, a global medical device company and the pioneer of Extracorporeal Shock Wave Lithotripsy (ESWL®), has received FDA clearance to market the Delta® III. This is the latest generation of the world’s best-selling and most clinically cited lithotripter, the Delta II.
To view the multimedia release go to:
https://www.multivu.com/players/English/8134451-dornier-medtech-delta-iii-kidney-stone-lithotripter/
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
Stashimi Inc., a new LA-based music, news and entertainment group dedicated to saving our collective attention spans, today announced that it will be releasing its flagship mobile app in conjunction with a signature event series dedicated to supporting emerging artists.
Working with a diverse list of rising talents like Mr. Carmack, Terrace Martin, Jesse Boykins III, SOSUPERSAM, Yung Jake and more, Stashimi will host producer workshops, EP releases, intimate shows with incredible lineups, and a touring university lecture series with former NPR hip-hop podcast Microphone Check, created by Ali Shaheed Muhammad (A Tribe Called Quest) and journalist Frannie Kelley.
"Artists drive culture, and Stashimi honors and reinforces that. Stashimi respects journalism, even thinks it’s necessary, but its allegiance is to the musician. And we second that emotion,” says Frannie Kelley and Ali Shaheed Muhammad.
To view the multimedia release go to:
http://www.multivu.com/players/English/7931251-stashimi-music-news-app-launch/
Since Newton witnessed a bubble rising from his bathtub, mankind has sought the stars. When William III of England commissioned Capt. William Kidd to command the first expedition to Mars in the late 1600s, he proved that space travel was both possible and profitable. Find out more at http://us.macmillan.com/arabellaofmars/daviddlevine-1 Arabella of Mars by David E Levine. Fantasy
This truly is one of the best demos ever
of our Overhead line of travel guitars guitars, and worth a watch if
not simply to hear Maneli play. If you’re considering buying a new
travel guitar, or are easily swayed to make an impulse purchase – be
careful – watching Maneli play the OF420 may just make you pull the
trigger on a new Journey Overhead… next thing you know you’ll be on
holiday picking away in a lounge chair overlooking some splendid view! One
of the greatest things about my job is the people I get to meet. Before
we even launched Journey Instruments, I saw Maneli Jamal’s “Movement
III” from his Ziur album on Youtube and I was totally floored. I
immediately bought his album and then sought him out for private
lessons on Skype (And learned a bastardized version of his ”Most
Glorious Day” song from the same album. Ha!). Though I had to quit
lessons due to the demands of running two companies and having my
second child, I kept in touch and have just loved watching him perform
and grow as an artist. Here we are 3 years later, and I’m humbled to
have Maneli make such an awesome demo video of our Overhead OF420
travel guitar
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Living Off the Grid - http://www.thriveoffthegrid.com/ - See how others are living offgrid using the advantages of wind and solar energy plus more for off grid power and ...
Living off the grid you must take advantage of renewable energy. This renewable resource originates from several sources, consisting of sun, wind and water, to start with ...
Researchers are constantly on the lookout for more ways of making green energy. Here are the 2 types you must understand now.
Living off the Grid: - Advantages of Solar Power
i. The energy that originates from simply one hour of sun suffices to supply energy for a year for the whole world
ii. A battery can be used to store off grid solar power for evenings and cloudy days
iii. Solar panels on a roof work when the sun's rays strike the cells in the panel and electrons are released, producing energy
iv. Using solar power will typically provide a saving of $100+ each month on utility costs for the property owners of off grid homes .
Living off the Grid: - Advantages of Wind Energy
i. When wind goes through the blades of a turbine that is connected to a generator, the energy produced by the spin is converted into electrical energy
ii. A single large wind turbine can provide electricity for around 500 off grid homes
iii. Last year, 42 % of the houses that were geared up with a source of off grid power used wind
iv. Unlike most other sources of energy, wind utilizes hardly any water; not only is wind energy carbon neutral, it helps water conservation also
v. There is around 10 times the amount of wind available in the U.S. than is needed to supply power for the whole country
vi. Wind energy is presently the fastest-growing source of renewable energy: - Around two wind farms are set up weekly in the U.S.
For living off the grid, the facts indicate that the advantages of solar power combined with the advantages of wind energy now exceed any advantages that fossil fuels may have had. However it is probably down to individuals to begin the shift to a larger scale adoption, so that we may all enjoy living off the grid.
Now that spring is here, flooding will be a major concern for many parts of the country.
The Northeast and Midwest received an abundance of snow this winter. Boston alone received more than 108 inches, making 2014-2015 the snowiest season in the city’s history. Until the frozen ground thaws, melting snow and heavy rains cannot be absorbed and the excess water can overflow streams, rivers, and lakes. The average National Flood Insurance Program flood claim between 2010 and 2014 was more than $42,000. Without flood insurance, you could be left to carry the financial burden of flood damage.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7338651-iii-weather-flood-insurance/
